| Arsenic | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 5, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 5, 2023 | Resolved | N/A |
| Chlorine | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Eye and nose irritation; stomach discomfort |
| Arsenic | Health-Based | N/A | 0.011 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.011 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Arsenic | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.011 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Arsenic | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Health-Based | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 20, 2022 | Active | N/A |
| Arsenic | Health-Based | N/A | 0.013 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.011 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.011 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| TTHM | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.011 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |